Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Rituximab-based first-line treatment of cGVHD after allogeneic SCT: results of a phase 2 study

Florent Malard, Myriam Labopin, Ibrahim Yakoub-Agha, Sylvain Chantepie, Thierry Guillaume, Didier Blaise, Reza Tabrizi, Leonardo Magro, Bernard Vanhove, Gilles Blancho, Philippe Moreau, Béatrice Gaugler, Patrice Chevallier, Mohamad Mohty

Blood (2017) 130 (20): 2186–2195.

https://doi.org/10.1182/blood-2017-05-786137

Published: 2017

Includes: Supplemental data

Journal Articles

Preventing Primate GvHD Using a Novel Antagonistic Anti-CD28 Antibody Plus Rapamycin: Downregulation of CD8 Activation and Preservation of the Naïve Cell Phenotype Predicts GvHD-Free Survival

Benjamin Watkins, MD, Aneesah P. Garrett, Jingyang Chen, Scott N. Furlan, MD, Kelly Hamby, Bernard Vanhove, PhD, Leslie S. Kean, MD PhD

Blood (2014) 124 (21): 2425.

https://doi.org/10.1182/blood.V124.21.2425.2425

Published: 2014

Journal Articles

Transplant tolerance is associated with reduced expression of cystathionine-γ-lyase that controls IL-12 production by dendritic cells and TH-1 immune responses

Romain Vuillefroy de Silly, Flora Coulon, Nicolas Poirier, Vojislav Jovanovic, Sophie Brouard, Véronique Ferchaud-Roucher, Gilles Blancho, Bernard Vanhove

Blood (2012) 119 (11): 2633–2643.

https://doi.org/10.1182/blood-2011-04-350546

Published: 2012

Journal Articles

Selective blockade of CD28 and not CTLA-4 with a single-chain Fv–α 1 -antitrypsin fusion antibody

Bernard Vanhove, Geneviève Laflamme, Flora Coulon, Marie Mougin, Patricia Vusio, Fabienne Haspot, Jérôme Tiollier, Jean-Paul Soulillou

Blood (2003) 102 (2): 564–570.

https://doi.org/10.1182/blood-2002-08-2480

Published: 2003

Journal Articles

Differential effect of CD28 versus B7 blockade on direct pathway of allorecognition and self-restricted responses

Fabienne Haspot, Florence Villemain, Geneviève Laflamme, Flora Coulon, Daniel Olive, Jérôme Tiollier, Jean-Paul Soulillou, Bernard Vanhove

Blood (2002) 99 (6): 2228–2234.

https://doi.org/10.1182/blood.V99.6.2228

Published: 2002

NARROW

Rituximab-based first-line treatment of cGVHD after allogeneic SCT: results of a phase 2 study

Preventing Primate GvHD Using a Novel Antagonistic Anti-CD28 Antibody Plus Rapamycin: Downregulation of CD8 Activation and Preservation of the Naïve Cell Phenotype Predicts GvHD-Free Survival

Transplant tolerance is associated with reduced expression of cystathionine-γ-lyase that controls IL-12 production by dendritic cells and TH-1 immune responses

Selective blockade of CD28 and not CTLA-4 with a single-chain Fv–α 1 -antitrypsin fusion antibody

Differential effect of CD28 versus B7 blockade on direct pathway of allorecognition and self-restricted responses

Email alerts

ASH Publications

American Society of Hematology

Rituximab-based first-line treatment of cGVHD after allogeneic SCT: results of a phase 2 study

Preventing Primate GvHD Using a Novel Antagonistic Anti-CD28 Antibody Plus Rapamycin: Downregulation of CD8 Activation and Preservation of the Naïve Cell Phenotype Predicts GvHD-Free Survival

Transplant tolerance is associated with reduced expression of cystathionine-γ-lyase that controls IL-12 production by dendritic cells and TH-1 immune responses

Selective blockade of CD28 and not CTLA-4 with a single-chain Fv–α 1 -antitrypsin fusion antibody

Differential effect of CD28 versus B7 blockade on direct pathway of allorecognition and self-restricted responses

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only